High aspartyl proteinase production and vaginitis in human immunodeficiency virus-infected women

Journal of Clinical Microbiology

Volumn 37, Issue 5, 1999, Pages 1376-1380

  De Bernardis, F ^a   Mondello, F ^a   Scaravelli, G ^b   Pachi A ^b   Girolamo, A ^a   Agatensi, L ^c   Cassone, A ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; FLUCONAZOLE; PEPSTATIN; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG TARGETING; ENZYME SYNTHESIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENICITY; PREVALENCE; PRIORITY JOURNAL; RAT; VAGINITIS; VIRULENCE;

ANIMALIA; CANDIDA ALBICANS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032897571     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.5.1376-1380.1999     Document Type: Article

References (38)

1. Agatensi, L., F. Franchi, F. Mondello, R. L. Bevilacqua, T. Ceddia, F. De Bernardis, and A. Cassone. 1991. Vaginopathic and proteolytic Candida species in outpatients attending a gynecology clinic. J. Clin. Pathol. 44:826-830.
2. Agresti, M. G., F. De Bernardis, F. Mondello, et al. 1994. Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. Eur. J. Epidemiol. 10:17-20.
3. Barchiesi, F., et al. Submitted for publication.
4. Barchiesi, F., R. J. Hollis, M. Delpoeta, D. A. McGough, G. Scalise, M. Rinaldi, and M. A. Pfaller. 1995. Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. Clin. Infect. Dis. 21:561-564.
5. Barchiesi, F. A., L. Colombo, D. A. McGough, A. W. Fothergill, and M. G. Rinaldi. 1994. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38: 1530-1533.
6. Bart-Delabesse, E., P. Boiron, A. Carlotti, and B. Dupont 1993. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J. Clin. Microbiol. 31:2933-2937.
7. Boerlin, P., F. Berlin-Petzold, C. Durussel, M. Addo, J. L. Pagani, J. P. Chave, and J. Bille. 1995. Cluster of oral atypical Candida albicans isolates in a group of human immunodeficiency virus-positive drug users. J. Clin. Microbiol. 33:1129-1135.
8. Brawner, D. L., and J. E. Cutler. 1989. Oral Candida albicans isolates from nonhospitalized normal carriers, immunocompetent hospitalized patients, and immunocompromized patients with or without acquired immunodeficiency syndrome. J. Clin. Microbiol. 27:1335-1341.
9. Bruatto, M., V. Vidotto, G. Marinuzzi, R. Raiteri, and A. Sinicco. 1991. Candida albicans biotypes in human immunodeficiency virus type 1-infected patients with oral candidiasis before and after antifungal therapy. J. Clin. Microbiol. 29:726-730.
10. + lymphocytes in resistance to mucosal candidiasis. Infect. Immun. 59:2447-2455.
11. Cassone, A., F. De Bernardis, F. Mondello, T. Ceddia, and L. Agatensi. 1987. Evidence for a correlation between proteinase secretion and vulvovaginal candidiasis. J. Infect. Dis. 156:777-783.
12. Cutler, J. E. 1991. Putative virulence factors of Candida albicans. Annu. Rev. Microbiol. 45:187-218.
13. De Bernardis, F., L. Agatensi, I. K. Ross, G. W. Emerson, R. Lorenzini, P. A. Sullivan, and A. Cassone. 1990. Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis. J. Infect. Dis. 161:1276-1283.
14. De Bernardis, F., M. Boccanera, L. Rainaldi, C. E. Guerra, I. Quinti, and A. Cassone. 1992. The secretion of aspartyl proteinase, a virulence enzyme, by isolates of Candida albicans from the oral cavity of HIV-infected subjects. Eur. J. Epidemiol. 8:362-367.
15. De Bernardis, F., A. Cassone, J. Sturtevant, and R. A. Calderone. 1995. Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect. Immun. 63:1887-1892.
16. De Bernardis, F., P. Chiani, M. Ciccozzi, G. Pellegrini, T. Ceddia, G. D'Offizi, I. Quinti, P. Sullivan, and A. Cassone. 1996. Elevated aspartyl proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect. Immun. 64:466-471.
17. De Bernardis, F., M. Boccanera, D. Adriani, E. Spreghini, G. Santoni, and A. Cassone. 1997. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65:3399-3405.
18. De Bernardis, F., S. Arancia, L. Morelli, B. Hube, D. Sanglard, W. Schäfer, and A. Cassone. Evidence that members of the secretory aspartyl proteinase gene family (SAP), in particular SAP2, are virulence factors for Candida vaginitis. J. Infect. Dis., in press.
19. Fothergill, A. W., and M. G. Rinaldi. 1994. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J. Clin. Microbiol. 32:59-64.
20. Gruber, A., E. Lukasser-Volg, M. Borg-von Zeplin, M. P. Dierich, and R. Wurzner. 1998. Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhanced Candida virulence in vitro. J. Infect. Dis. 177:1057-1063.
21. Holmberg, K., and R. D. Meyer. 1986. Fungal infections in patients with AIDS and AIDS-related complex. Scand. J. Infect. Dis. 18:179-185.
22. Hube, B. 1996. Candida albicans secreted aspartyl proteinases. Curr. Top. Med. Mycol. 7:55-69.
23. Iman, N., C. J. Carpenter, H. M. Kenneth, A. Fisher, M. Stein, and S. B. Danforth. 1990. Hierarchical pattern of mucosal candidal infection in HIV-seropositive women. Am. J. Med. 89:142-146.
24. Johnson, M. E., D. W. Warnok, J. Lukers, S. R. Porter, and C. Scully. 1995. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J. Antimicrob. Chemother. 35:103-114.
25. Kaminishi, H., H. Miyaguchi, T. Tamaki, N. Suenaga, M. Hisamatsu, I. Mihashi, H. Matsumoto, H. Maeda, and Y. Hagihara. 1995. Degradation of humoral host defense by Candida albicans proteinase. Infect. Immun. 63: 984-988.
26. Klein, R. S., C. A. Harris, C. Butkus Small, B. Moll, M. Lesser, and G. H. Friendland. 1984. Oral candidiasis in high risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311:354-357.
27. Lupetti, A., G. Guzzi, A. Paladini, K. Swart, M. Campa, and S. Senesi. 1995. Molecular typing of Candida albicans in oral candidiasis: karyotype epidemiology with human immunodeficiency virus-positive patients in comparison with that with healthy carriers. J. Clin. Microbiol. 33:1238-1248.
28. Mondello, F., A. Guglielminetti, A. Torosantucci, T. Ceddia, L. Agatensi, and A. Cassone. 1986. Yeast species isolated from outpatients with vulvovaginal candidosis attending a gynecological center in Rome. IRCS (Int. Res. Commun. Syst.) Med. Sci. 14:746-747.
29. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M27-T, vol. 15. National Committee for Clinical Laboratory Standards, Wayne, Pa.
30. Odds, F. C. 1988. Candida and candidosis. Baillière Tindall, London, United Kingdom.
31. Ollert, M. W., C. Wende, M. Gorlich, C. G. McMullan-Vogel, M. Borg-Von Zepelin, C. W. Vogel, and H. C. Korting. 1995. Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients. J. Clin. Microbiol. 33:2543-2549.
32. Quinti, I., C. Palma, E. C. Guerra, M. J. Gomez, I. Mezzaroma, F. Aiuti, and A. Cassone. 1991. Proliferative and cytotoxic responses to mannoproteins of Candida albicans by peripheral blood lymphocytes of HIV-infected subjects. Clin. Exp. Immunol. 85:485-492.
33. Ruchel, R., F. De Bernardis, T. L. Ray, P. A. Sullivan, and G. T. Cole. 1992. Candida acid proteinases. J. Med. Vet. Mycol. 29(Suppl.):1-9.
34. Schmid, J., F. C. Odds, M. J. Wiselka, G. Nicholson, and D. R. Soll. 1992. Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting. J. Clin. Microbiol. 30:935-941.
35. Sullivan, D., D. Bennett, M. Henman, P. Harwood, S. Flint, F. Mulcahy, D. Shanley, and D. Coleman. 1993. Oligonucleotide fingerprinting of isolates of Candida species other than C. albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients. J. Clin. Microbiol. 31:2124-2133.
36. Torosantucci, A., C. Bromuro, M. J. Gomez, C. M. Ausiello, F. Urbani, and A. Cassone. 1993. Identification of a 65 kDa mannoprotein constituent as a main target of human cell-mediated immune response to Candida albicans. J. Infect. Dis. 168:427-435.
37. Tsuchiya, T., M. Taguchi, Y. Fukazawa, and T. Shinoda. 1984. Serological characterization. Methods Microbiol. 16:75-76.
38. Whelan, W. L., D. R. Kirsch, K. J. Kwon-Cjiung, S. M. Wahl, and P. D. Smith. 1990. Candida albicans in patients with the acquired immunodeficiency syndrome: absence of a novel or hypervirulent strain. J. Infect. Dis. 162:513-518.